SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *\[Explanation\]*
=============================================================

**Intravenous versus intraosseous route for achieving parenteral accessPatient or population:** adults or children requiring fluid delivered by a parenteral route (one study testing insertion and the volume of fluid delivered in manikins by practitioners wearing protective equipment was also included)**Settings:** India (emergency unit) and USA (pre-hospital care)**Intervention:** intravenous route**Comparison:** intraosseous route**OutcomesIllustrative comparative risks\* (95% CI)Relative effect(95% CI)No of participants(studies)Quality of the evidence(GRADE)CommentsAssumed riskCorresponding riskIntraosseous routeIntravenous routeInsertion failures**Study populationRR 3.89(2.39 to 6.33)242(2 RCTs)⊕⊕⊕○LOW ^1,2^-12 per 10047 per 100(29 to 76)**Time to infusion/placement**We did not combine data due to substantial variation in the average time taken to insert parenteral access between trials. The estimates from all 4 trials suggest that the IV route takes longer to insert than IO. Although we are confident that the time to infusion is shorter with IO, we cannot be certain about the size of the effect because the magnitude of the difference varied considerably between trials-342(4 RCTs)⊕⊕⊕○MODERATE ^1,^-**Dislodgement of device during infusion**Study populationRR 0.53(0.18 to 1.55)182(1 RCT)⊕⊕⊕○LOW ^1,3^-113 per 100060 per 1000(20 to 175)**Needlestick injuries**No studies reported this outcomeNo studies reported this outcome-NANA-**Volume of fluid infused**The mean volume of fluid infused (ml) in the IO group was 800The mean volume of fluid infused (ml) in the IV group was 400 higher (365 higher to 434 higher)-182(1 RCT)⊕⊕⊕○MODERATE ^1^-\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: confidence interval; IO: intraosseous; IV: intravenous; NA: not applicable; RCT: randomised controlled trial; RR: risk ratioGRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate.[^4][^5][^6]

Background
==========

Description of the condition
----------------------------

Ebola virus disease (EVD) is a severe infection with a high case-fatality rate (WHO [@b53]). West Africa is currently (November 2014) experiencing the largest recorded outbreak of EVD with many hundreds of new cases per week (WHO [@b53]). EVD is characterised by sudden onset of fever followed by nausea, vomiting and diarrhoea. The associated fluid loss, which can be as much as five to 10 litres per day (Kreuels [@b41]; Ribner [@b44]), leads to electrolyte abnormalities and profound intravascular volume depletion (Feldmann [@b35]; Sanchez [@b47]). Case series show that in people with fatal EVD, blood levels of urea and creatinine increase over time, which may be a consequence of dehydration (Schieffelin [@b48]). Fluid administration is therefore recommended as a key part of supportive care to reduce mortality in patients with EVD (WHO [@b52]).

Description of the intervention
-------------------------------

Many patients with EVD have nausea, difficulty swallowing and severe vomiting, which limit the usefulness of oral rehydration. Similarly, severe diarrhoea limits the usefulness of rectal fluid administration. In these patients, parenteral fluids can be given to prevent and treat dehydration.

There are four main ways of achieving parenteral access to administer fluids: intravenous, intraosseous, subcutaneous and intraperitoneal.

Intravenous access involves the delivery of fluids or medications directly into a vein. There are two types of venous access - central and peripheral. Central venous catheters involve placing a cannula into one of the large veins as it enters the body\'s trunk (most commonly the internal jugular, subclavian or femoral veins) and advancing until the tip of the catheter sits in the superior vena cava, or the iliac vein in the case of the femoral catheter. Peripheral cannulae are placed in a limb or (rarely) the scalp;Intraosseous access involves the insertion of a needle into the bone marrow (usually in the tibia or the humerus, or less commonly in the pelvis or sternum) to which an infusion line is connected. It is often used in patients for whom intravenous access is difficult to achieve, such as those with collapsed peripheral veins and young children. Intraosseous needles can be inserted manually, although the use of mechanical insertion devices, such as the BIG Bone Injection Gun® and Arrow® EZ-IO® Intraosseous Vascular Access System, have become common. A pressurised fluid bag is required to ensure that the fluid runs;Subcutaneous access involves the insertion of a needle or catheter into the subcutaneous tissue that lies beneath the dermis and epidermis layers. Hyaluronidase may be given to improve absorption of infused substances into the circulation. Common sites for subcutaneous infusion are the abdomen, thigh and upper arm;Intraperitoneal access involves placing a catheter through the abdominal wall and the delivery of fluids into the peritoneal cavity, in similarity with peritoneal dialysis. This approach has been used in resource poor settings to resuscitate children with severe diarrhoea due to cholera infection (Mahalanabis [@b25]).

The intravenous route is the most commonly used method for administering fluids (Waitt [@b51]). However, securing intravenous access can be technically difficult in sick and dehydrated patients and is likely to be particularly challenging for healthcare workers obliged to wear personal protective equipment (PPE). Staff shortages and limitation of time spent at the bedside due to the challenge of wearing PPE for long periods in a hot environment may also frustrate efforts to achieve intravenous access in large numbers of sick patients (Fowler [@b36]). Securing parenteral access may also present risks to healthcare workers, e.g. needlestick injury or inadvertent contact with body fluids associated with insertion or dislodgement of parenteral access. For these reasons, an understanding of the relative merits of alternative routes (intravenous, intraosseous, subcutaneous or intraperitoneal) for achieving parenteral access could be important for the management of patients with EVD. The different approaches are likely to vary in terms of ease of insertion and effectiveness for fluid replacement.

Why it is important to do this review
-------------------------------------

Due to the large number of cases and resource constraints, it is essential that parenteral access in patients with EVD can be achieved quickly and maintained with minimal clinical intervention. We have therefore conducted a systematic review of randomised controlled trials comparing alternative routes for achieving parenteral access to assess their effectiveness and safety in terms of ease of insertion and effectiveness for fluid replacement.

This Cochrane review has been prompted by the ongoing EVD crisis in West Africa and the need to identify ways to improve the medical care of those affected. However, we have not limited the inclusion criteria to patients with EVD as we anticipated that it was unlikely that we would find any trial research conducted in this specific patient group. We believe that evidence derived from trials involving patients who require insertion of parenteral access for other indications is relevant to the management of patients with EVD, as well as to the wider range of patients who require parenteral infusions.

Objectives
==========

To compare the reliability, ease of use and speed of insertion of different parenteral access methods.

Methods
=======

Criteria for considering studies for this review
------------------------------------------------

### Types of studies

Randomised controlled trials.

Eligible trials were those judged to have assigned participants using a method of random allocation (e.g. computer-generated randomisation, random numbers table or drawing lots) or a quasi-random method of allocation (e.g. alternation, date of birth or case record number) (definition adapted from Box 6.3.a in Lefebvre [@b42]).

### Types of participants

People of any age in whom insertion of a parenteral access method is attempted for the purpose of infusing fluids or medication.

Trials involving the insertion of parenteral access under simulated conditions, such as using manikins or cadavers in which healthcare workers are randomly allocated to insert different parenteral access methods, were also eligible.

### Types of interventions

We considered the following parenteral access methods: intravenous (central venous access and peripheral venous access), intraperitoneal, subcutaneous and intraosseous (using both manual and mechanical methods). We planned to explore the effects of central venous access and peripheral venous access separately.

Only trials comparing two or more of the above parenteral routes were eligible.

### Types of outcome measures

#### Primary outcomes

Success of route placement (\'success\'/\'failure\' as defined in the individual trial).

#### Secondary outcomes

Time to infusion/placement.Average number of insertion attempts.Dislodgement of device during infusion.Time period with functional access.Local site reactions (e.g. infusion site pain, swelling, infection).Clinician\'s perception of ease of administration.Needlestick injury to healthcare workers.Patient\'s discomfort.Mortality.

For trials assessing parenteral routes for fluid administration, we extracted data on the following outcomes:

Volume of fluid infused.Electrolyte levels and renal function (changes in serum sodium, potassium, urea and creatinine).

Search methods for identification of studies
--------------------------------------------

In order to reduce publication and retrieval bias we did not restrict our search by language, date or publication status.

### Electronic searches

We searched the following databases:

Cochrane Injuries Group Specialised Register (17 November 2014);Cochrane Central Register of Controlled Trials (CENTRAL, *The Cochrane Library*) (issue 10 of 12, 2014);Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (1946 to 17 November 2014);Embase Classic + Embase (OvidSP) (1947 to 17 November 2014);CINAHL Plus (EBSCO) (1937 to 17 November 2014);Clinicaltrials.gov (<http://www.clinicaltrials.gov>) (accessed 17 November 2014).

We adapted the MEDLINE search strategy (Appendix 1) as necessary for each of the other databases: the added study filter is a modified version of the Ovid MEDLINE(R) Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre [@b42]). For the Embase search strategy we added the study design terms used by the UK Cochrane Centre (Lefebvre [@b42]).

### Searching other resources

We screened the reference lists of the eligible trials and review articles for further potentially eligible studies. We also searched the internet using the Google search engine (<http://www.google.com>) with selected terms from the search strategy to identify further unpublished or grey literature.

Data collection and analysis
----------------------------

### Selection of studies

Two review authors (KK and DB, IR or HS) independently examined the records identified from the search and screened them by reviewing the title and abstract. We obtained the full texts of potentially eligible studies and two review authors assessed whether each study met the inclusion criteria. We resolved disagreements through discussion or by asking a third review author (IR).

### Data extraction and management

Two review authors (KK and GT) independently extracted data using a data extraction form designed specifically for the review. We extracted data on the following:

patient characteristics (including age, sex, indication for parenteral access);intervention characteristics (including description of parenteral routes, use of PPE);trial methods (specifically information for \'Risk of bias\' assessment);outcome data.

We resolved any disagreements about the extracted data by discussion or by asking a third review author (IR).

### Assessment of risk of bias in included studies

Two review authors (KK and GT) assessed the risk of bias in the included trials using The Cochrane Collaboration\'s \'Risk of bias\' tool, as described by Higgins [@b38]. We assessed the following domains for each trial: sequence generation, allocation concealment, blinding (participants, personnel and outcome assessment), incomplete outcome data and selective outcome reporting. We completed a \'Risk of bias\' table, incorporating a description of the trial against each of the domains and a judgement of the risk of bias, as follows: \'low risk\', \'high risk\' or \'unclear risk\' of bias.

For the \'blinding of outcome assessment\' and \'incomplete outcome data\' domains, we assessed the risk of bias by outcome group as follows.

Outcomes related to parenteral route insertion (success of route placement; number of insertion attempts; dislodgement of device during infusion; time period with functional access).Clinical outcomes (sodium; potassium; urea; creatinine; mortality).Subjective outcomes (local site reactions, complications; clinician\'s perception of ease of administration; volume of fluid infused; needlestick injury to healthcare workers; patient\'s discomfort).

### Measures of treatment effect

For binary outcome data, we calculated risk ratios and 95% confidence intervals (CI) and for continuous outcome data we calculated the mean difference and 95% CI for each trial. In a number of trials, summary continuous data were presented as medians and ranges; in these cases, for the purpose of meta-analysis, we estimated the corresponding means and standard deviations using the method described in Hozo [@b40] ([Appendix 2](#app2){ref-type="app"}).

### Unit of analysis issues

For cross-over trials, we extracted effect estimates from an appropriate paired analysis from the trial reports or we calculated these where possible. We included these estimates in the meta-analysis using the generic inverse variance method. However, if a cross-over trial presented data according to the treatment group, we analysed the results from both periods of the cross-over trial as if they had originated from a parallel design. This latter approach leads to a unit of analysis error, causing the CIs to be too wide and the trial to receive too little weight. However, we think that the resulting conservative estimates are preferable to omitting all such data from the analyses.

Cluster-randomised controlled trials that reported effect estimates and confidence intervals derived from an appropriate analysis (e.g. generalised estimating equations or multi-level modelling) would have been included in the meta-analysis using the generic inverse variance method. Alternatively, if any such trial had analysed data at the level of the participant rather than at the cluster level, we would have attempted an approximate analysis as described in Higgins [@b39], assuming an estimate of the intracluster correlation coefficient was available.

For trials involving multiple intervention groups, we followed the approach described in Higgins [@b39]. Where there were multiple groups receiving the same parenteral access method, we combined these to create a single pair-wise comparison with a group receiving an alternative parenteral method.

### Dealing with missing data

We analysed trial results on an intention-to-treat basis where the necessary data were available. Where data in the trial reports were not presented on an intention-to-treat basis but information about exclusions was presented, we \'re-included\' exclusions to allow for inclusion in the meta-analysis as intention-to-treat. Otherwise, we used the data available from the trial report and conducted an available-case analysis.

### Assessment of heterogeneity

We assessed trial characteristics in terms of participants, interventions and outcomes for clinical heterogeneity.

We examined statistical heterogeneity by visual inspection of forest plots, and by using the I² statistic and the Chi² test. The I² statistic describes the percentage of total variation across studies due to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity and larger values show increasing heterogeneity; substantial heterogeneity is considered to exist when I² is greater than 50% (Deeks [@b34]). For the Chi² test, we used a P value of less than 0.10 to indicate the presence of statistically significant heterogeneity.

We anticipated that differences in the definition of the primary outcome, \'success\'/\'failure\' of insertion, between individual trials might be a potential source of heterogeneity.

### Assessment of reporting biases

We planned to investigate the presence of reporting (publication) bias using funnel plots if there were at least 10 trials for the same outcome in the analysis.

### Data synthesis

Where we judged the included trials to be too clinically heterogeneous to pool, we described the results narratively. When we considered a pooled analysis to be appropriate, we combined effect estimates using the fixed-effect model (also known as the weighted-average method). We consider this approach to be preferable to the random-effects model, which can give too much weight to smaller trials that are often of poorer methodological quality.

#### Required sample size

Using TSA [@b50] software, we estimated that a total sample size of 1388 would be required for the meta-analysis of our primary outcome to detect an intervention effect reliably. This estimate is based on an assumed baseline event rate of 50%, with 90% power to detect a clinically relevant difference of 20% at the 5% significance level, adjusted for heterogeneity anticipated at I² = 25%.

### Subgroup analysis and investigation of heterogeneity

We conducted subgroup analyses to examine whether the effects of the parenteral route of fluid administration varied by age of patient (child versus adult) and use of PPE (PPE versus no PPE), assuming that there was at least one trial in each subgroup.

### Sensitivity analysis

We conducted sensitivity analyses to quantify the effects when restricted to trials with adequate allocation concealment, assuming that there was at least one trial contributing data to the analysis.

#### Summary of findings

We have also included the results of the review for the following outcomes in \'Summary of findings\' tables. We included information about the following outcomes:

success of route placement;time to placement/start to infusion;dislodgement of device during infusion;volume of fluid infused;needlestick injuries.

We used GRADEpro [@b37] to prepare the tables. We judged the overall quality of the evidence for each outcome as \'high\', \'moderate\', \'low\' or \'very low\' according to the GRADE approach ([@b49]). We considered the following:

impact of the risk of bias of individual trials;precision of the pooled estimate;inconsistency or heterogeneity (clinical, methodological and statistical);indirectness of evidence;impact of selective reporting and publication bias on effect estimate.

Results
=======

Description of studies
----------------------

### Results of the search

The trial selection process is summarised in Figure [1](#fig01){ref-type="fig"}. The combined search strategy identified 1276 records, of which we judged 36 to be potentially eligible and obtained the full texts. After a full-text review, we included 17 trials in the review, which involved 21 eligible pair-wise comparisons.

![Study flow diagram.](CD011386-0001-f1){#fig01}

### Included studies

Full details of each trial are presented in the Characteristics of included studies table; a summary is given below.

#### Design

Ten trials were randomised, parallel-group trials and seven were randomised, cross-over trials.

Of the seven cross-over trials, five involved a two-period comparison, one a four-period comparison and one a three-period comparison.

#### Sample sizes

The 17 trials included a combined total of 885 participants, of whom 847 were patients requiring parenteral access and 38 were health personnel who were attempting parenteral access under simulated conditions. The median sample size was 37 (range 6 to 182). One hundred and five participants were included in the cross-over trials and therefore acted as their own control.

#### Setting and participants

One trial was multicentre, conducted in 11 European countries. The remaining trials were conducted in Denmark (n = 1), France (n = 5), Germany (n = 1), India (n = 1), Spain (n = 1), Sweden (n = 1), the USA (n = 3) and the UK (n = 3).

None of the included trials involved patients with Ebola virus disease (EVD) or were conducted in the context of a similar medical emergency. Instead, the included trials were conducted in the following clinical settings: two involved the treatment of children with dehydration in hospital; one involved patients receiving a bone marrow transplant; six involved hospitalised elderly patients requiring parenteral fluids to maintain or restore hydration; three involved the infusion of insulin in patients with diabetes; one involved patients with multifocal neuropathy being treated with immunoglobulin; one involved patients with malignant disease in an oncology department; one involved paramedics attending out-of-hospital cardiac arrests; one involved paramedic trainees attempting parenteral access on cadavers in a hospital training laboratory; and one involved doctors and nurses attempting parenteral access on manikins in a pre-hospital department.

Fifteen trials compared different parenteral routes in patients; 14 involved adults and one involved children (Banerjee [@b1]). The other two studies by Lamhaut et al and Hubble [@b10] used a cross-over design to assign medical personnel to attempt different parenteral routes. Training manikins were used in Lamhaut and cadavers in Hubble [@b10].

The purpose of the parenteral access was for the infusion of fluids in 11 trials (Banerjee [@b1]; Challiner [@b3]; Dardaine [@b4]; Delamaire [@b5]; Duems [@b6]; Hubble [@b10]; Lamhaut [@b11]; Lamhaut [@b12]; [@b14]; Reades [@b15]; Slesak [@b17]; Spandorfer [@b18]), and for the infusion of medication (including insulin, bone marrow, immunoglobulin and bleomycin) in six trials ([@b2]; [@b7]; Harbo [@b8]; Harvey [@b9]; Liebl [@b13]; Selam [@b16]).

#### Interventions

The included trials compared the following:

Intravenous access versus intraosseous access, *four trials* (Banerjee [@b1]; [@b7]; Lamhaut [@b11]; Lamhaut [@b12]; Reades [@b15]).Intravenous access versus subcutaneous access, *11 trials* ([@b2]; Challiner [@b3]; Dardaine [@b4]; Delamaire [@b5]; Duems [@b6]; Harbo [@b8]; Harvey [@b9]; [@b14]; Selam [@b16]; Slesak [@b17]; Spandorfer [@b18]).Intravenous access versus intraperitoneal access, *one trial* (Selam [@b16]).Saphenous vein cutdown versus intraosseous access, *one trial* (Hubble [@b10]).Intraperitoneal access versus subcutaneous access, *one trial* (Selam [@b16]).

All of the trials assessing the intravenous method involved peripheral intravenous access.

One cross-over trial by Lamhaut et al compared intravenous and intraosseous insertion with and without the wearing of PPE. For the purpose of the meta-analysis, we considered separately the data for the comparison of intravenous and intraosseous insertion without PPE (Lamhaut [@b11]) and with PPE (Lamhaut [@b12]).

The trial by Reades et al compared intravenous access with two intraosseous groups; one involved insertion into the humerus and the other into the tibia (Reades [@b15]). For the purpose of the meta-analysis, we combined the data from the two intraosseous groups to derive a single comparison with the intravenous group.

The cross-over trial by Selam et al compared three parenteral methods for administering insulin - intravenous, subcutaneous and intraperitoneal (Selam [@b16]). We considered separately the results from the three single pair-wise comparisons (intravenous versus subcutaneous, intravenous versus intraperitoneal, and subcutaneous versus intraperitoneal) in this review.

#### Outcomes

The trials reporting data on the outcomes of interest are as follows:

Success of route of insertion, *six trials*.Time to infusion/placement, *four trials*.Number of insertion attempts, *one trial*.Dislodgement of device during infusion, *two trials*.Time period with functional access, *one trial*.Local site reactions (e.g. erythema, oedema, swelling, infection), *11 trials*.Clinician\'s perception of ease of administration, *three trials*.Needlestick injury to healthcare workers; *no trials*.Patient\'s discomfort (pain or discomfort); *five trials*.Mortality, *two trials*.Volume of fluid infused, *five trials*.Serum sodium, *two trials*.Serum potassium, *one trial*.Urea, *two trials*.Creatinine, *three trials*.

### Excluded studies

A list of excluded studies with the reasons for their exclusion is presented in Characteristics of excluded studies.

Risk of bias in included studies
--------------------------------

Our judgements regarding each \'Risk of bias\' item for each included trial are presented in Figure [2](#fig02){ref-type="fig"}.

![\'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.](CD011386-0001-f2){#fig02}

### Allocation

#### Sequence generation

One trial alternately assigned patients into groups and we judged it to be at high risk of bias (Banerjee [@b1]). Four trials used an adequate method of sequence generation and we judged them to be at low risk of bias; of these, one trial referred to a random numbers table ([@b14]), and three used computer-generated randomisation (Challiner [@b3]; Lamhaut [@b11]; Lamhaut [@b12]; Spandorfer [@b18]). We rated the remaining 12 trials as unclear due to insufficient information ([@b2]; Dardaine [@b4]; Delamaire [@b5]; Duems [@b6]; [@b7]; Harbo [@b8]; Harvey [@b9]; Hubble [@b10]; Liebl [@b13]; Reades [@b15]; Selam [@b16]; Slesak [@b17]).

#### Allocation concealment

We judged allocation to have been inadequately concealed and at high risk of bias in two trials (Banerjee [@b1]; Reades [@b15]). Two trials used a method of central allocation (Harbo [@b8]; Spandorfer [@b18]), and one trial used sequentially numbered, sealed envelopes (Challiner [@b3]); we considered all three to be adequately concealed and at low risk of bias. We rated the remaining 12 trials as unclear due to insufficient information ([@b2]; Dardaine [@b4]; Delamaire [@b5]; Duems [@b6]; [@b7]; Harvey [@b9]; Hubble [@b10]; Lamhaut [@b11]; Lamhaut [@b12]; Liebl [@b13]; [@b14]; Selam [@b16]; Slesak [@b17]).

### Blinding

#### Blinding of participants and personnel

Due to the nature of the interventions under study, it was not feasible for participants and personnel to be blinded to allocation status and we judged all 17 trials to be at high risk of bias, although it is unclear in which direction the results would have been biased.

#### Blinding of outcome assessment

##### Outcomes related to parenteral route insertion

We judged that measurement of these outcomes was likely to have been influenced by lack of blinding so we judged all 10 trials reporting data on these outcomes to be at high risk of bias (Banerjee [@b1]; Challiner [@b3]; Dardaine [@b4]; Delamaire [@b5]; Duems [@b6]; Hubble [@b10]; Lamhaut [@b11]; Lamhaut [@b12]; Reades [@b15]; Slesak [@b17]; Spandorfer [@b18]).

##### Clinical outcomes

We judged that measurement of these outcomes was not likely to have been influenced by lack of blinding so we judged all four trials reporting data on these outcomes to be at low risk of bias (Banerjee [@b1]; Challiner [@b3]; Duems [@b6]; Slesak [@b17]).

##### Subjective outcomes

We judged that measurement of these outcomes was likely to have been influenced by lack of blinding so we judged all 13 trials reporting data on these outcomes to be at high risk of bias ([@b2]; Challiner [@b3]; Delamaire [@b5]; Duems [@b6]; [@b7]; Harbo [@b8]; Harvey [@b9]; Liebl [@b13]; [@b14]; Reades [@b15]; Selam [@b16]; Slesak [@b17]; Spandorfer [@b18]).

### Incomplete outcome data

#### Outcomes related to parenteral route insertion

Of the 11 trials reporting data on one or more of these outcomes, we judged three to be at high risk of bias (Banerjee [@b1]; Challiner [@b3]; Duems [@b6]), and eight at low risk of bias (Dardaine [@b4]; Delamaire [@b5]; Hubble [@b10]; Lamhaut [@b11]; Lamhaut [@b12]; Reades [@b15]; Slesak [@b17]; Spandorfer [@b18]).

#### Clinical outcomes

Of the six trials reporting data on one or more of these outcomes, we judged three to be at high risk of bias (Banerjee [@b1]; Duems [@b6]; [@b14]), and three at low risk of bias (Challiner [@b3]; Reades [@b15]; Slesak [@b17]).

#### Subjective outcomes

Of the 13 trials reporting data on one or more of these outcomes, we judged four to be at high risk of bias (Duems [@b6]; [@b7]; Liebl [@b13]; [@b14]), and nine at low risk of bias ([@b2]; Challiner [@b3]; Delamaire [@b5]; Harbo [@b8]; Hubble [@b10]; Reades [@b15]; Selam [@b16]; Slesak [@b17]; Spandorfer [@b18]).

### Selective reporting

We found clinical trial registration records for two trials, both of which had been registered after the start of recruitment. For one of these trials, outcomes not mentioned in the registration record were reported within the final report so we judged this trial to be at high risk of bias (Reades [@b15]). There were no apparent differences in the specified outcomes for the second trial, which we judged to be at unclear risk of bias due to the retrospective registration (Harbo [@b8]). We also judged the risk of bias for the remaining 15 trials to be unclear as we had insufficient information to permit judgement.

Effects of interventions
------------------------

See: **Summary of findings for the main comparison** Intravenous versus intraosseous route for achieving parenteral access; **Summary of findings 2** Intravenous versus subcutaneous route for achieving parenteral access; **Summary of findings 3** Saphenous vein cutdown versus intraosseous route for achieving parenteral access

### Peripheral intravenous versus intraosseus access

We have presented separately two effect estimates from one four-period cross-over trial in the analyses but have not combined these with data from parallel-group trials (Lamhaut [@b11]; Lamhaut [@b12]).

#### Insertion failures

Insertion failures were reported by three trials (Banerjee [@b1]; Lamhaut [@b11]; Lamhaut [@b12]; Reades [@b15]). The data from Lamhaut [@b11] and Lamhaut [@b12] originated from the same cross-over trial, therefore we did not pool these data in the meta-analysis. Furthermore, as there were no failures in either Lamhaut [@b11] or Lamhaut [@b12] treatment effects for these comparisons could not be estimated. The pooled estimate is therefore based on data from Banerjee [@b1] and Reades [@b15]. More patients in the intravenous group experienced an insertion failure than in the intraosseous group (risk ratio (RR) 3.89, 95% confidence interval (CI) 2.39 to 6.33; n = 242; P value \< 0.0001) (Analysis 1.1). There was moderate statistical heterogeneity between trials (I² = 48%), however it was not statistically significant (Chi² P value = 0.16) and the direction of the effect estimates was consistent.

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings for the main comparison).

##### Subgroup analysis

There was no evidence of a difference in effect according to the age of participants. The risk of insertion failure was higher in the intravenous group in both the one trial involving adults (RR 3.24, 95% CI 2.00 to 5.27; n = 182; P value \< 0.0001) (Reades [@b15]), and the one trial involving children (RR 21.00, 95% CI 1.29 to 342.93; n = 60; P value = 0.03) (Banerjee [@b1]) (test for subgroup differences: Chi² = 1.67, df = 1 (P value = 0.20), I² = 40.1%) (Analysis 1.2).

#### Time to infusion/placement

Time to infusion/placement was reported by three trials (Banerjee [@b1]; Lamhaut [@b11]; Lamhaut [@b12]; Reades [@b15]). Due to clinical heterogeneity we did not calculate a pooled estimate, although effect estimates from each trial are presented on a forest plot to provide a visual summary. It took longer to achieve intravenous access than intraosseous access in all trials, with the difference reaching statistical significance in two trials but not in the third (Analysis 1.3).

In Reades [@b15], the data for the humerus intraosseous and tibia intraosseous groups were combined for the analysis, although we note that there was a difference in the average time taken for insertion between the sites: mean ± standard deviation (SD) for humeral insertion = 420 seconds ± 91.50 and for tibial insertion = 276 seconds ± 39.75.

We rated the quality of the evidence as moderate according to GRADE, as we downgraded it for risk of bias (Summary of findings for the main comparison).

#### Average number of insertion attempts

The average number of insertion attempts was reported by one trial (Reades [@b15]). There was no difference between the two groups (mean difference (MD) 0.00, 95% CI -0.07 to 0.07; n = 182; P value = 1.00) (Analysis 1.4).

#### Dislodgement of device during infusion

Dislodgement of the device during infusion was reported by one trial (Reades [@b15]). There were fewer dislodgements in the intravenous access group, although the difference is not statistically significant (RR 0.53, 95% CI 0.18 to 1.55; n = 182; P value = 0.25) (Analysis 1.5). Most of the dislodgements (10/13) occurred in the intraosseous patients who had the device inserted into the proximal humerus.

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings for the main comparison).

#### Time with functional access

None of the trials reported data on this outcome.

#### Local site reactions

##### Infection

One trial, involving the infusion of bone marrow, reported number of patients who developed bacteraemia during the first month ([@b7]). There were fewer cases of bacteraemia in the intravenous group, although the difference was not statistically significant (RR 5.57, 95% CI 0.35 to 88.77; n = 28; P value = 0.22) (Analysis 1.6).

#### Clinician\'s perception of administration of access route

One trial measured the paramedics\' perception of how comfortable they felt when administering each method to each patient (Reades [@b15]). Paramedics were less likely to report that they were uncomfortable when inserting via the intravenous route (RR 0.15, 95% CI 0.04 to 0.61; n = 182; P value = 0.008) (Analysis 1.7).

#### Needlestick injuries

None of the trials reported data on this outcome.

#### Patient discomfort

None of the trials reported data on this outcome.

#### Mortality

None of the trials reported data on this outcome.

#### Volume of fluid infused

The volume of fluid infused was reported by one trial (Reades [@b15]). A larger volume of fluid was infused via the intravenous route than the intraosseous route (MD 400 ml, 95% CI 365.57 to 434.43; n = 182; P value \< 0.0001) (Analysis 1.8).

We rated the quality of the evidence as moderate according to GRADE, as we downgraded it for risk of bias (Summary of findings for the main comparison).

#### Electrolyte level

Electrolyte level was reported by one trial (Banerjee [@b1]). There was no evidence of a difference in serum sodium (MD -1.00, 95% CI -5.36 to 3.36; n = 60; P value = 0.65) or potassium (MD -0.40, 95% CI -2.97 to 2.17; n = 60; P value = 0.76) between groups (Analysis 1.9).

#### Renal function

Renal function was reported by one trial (Banerjee [@b1]). The average levels of both urea and creatinine were lower in the intravenous group; the difference was not statistically significant for urea (MD -5.00, 95% CI -10.53 to 0.53; n = 60; P value = 0.08), but it was statistically significant for creatinine (MD -35.00, 95% CI -44.66 to -25.34; n = 60; P value \< 0.0001) (Analysis 1.10).

#### Sensitivity analysis

Sensitivity analysis was not possible as we judged none of the trials comparing intravenous and intraosseous access to be at low risk of bias for allocation concealment.

### Peripheral intravenous versus subcutaneous access

#### Insertion failures

Insertion failures were reported by three trials (Delamaire [@b5]; [@b14]; Spandorfer [@b18]). More patients in the intravenous group experienced an insertion failure than in the subcutaneous group (RR 14.79, 95% CI 2.87 to 76.08; n = 238) (Analysis 2.1). There was no statistical heterogeneity between trials (Chi² P value = 0.50; I² = 0%).

We rated the quality of the evidence as moderate according to the GRADE system, as we downgraded it for imprecision (Summary of findings 2).

##### Sensitivity analysis

The effect remained when we restricted the analysis to the one trial with adequate allocation concealment (Spandorfer [@b18]) (RR 32.13, 95% CI 1.96 to 525.87; n = 148; P value = 0.01) (Analysis 2.2).

##### Subgroup analysis

Two trials involved adults (Delamaire [@b5]; [@b14]), and one trial involved children (Spandorfer [@b18]). The effect estimates for both subgroups were consistent, with an increased risk of insertion failures in the intravenous group, although the effect was not statistically significant for the subgroup of trials involving adults (*adults* RR 6.00, 95% CI 0.76 to 47.39; n = 90; P value = 0.09 versus *children* RR 32.13, 95% CI 1.96 to 525.87; n = 148; P value = 0.01). However, there is no evidence that the effect varied between these subgroups (test for subgroup differences: Chi² = 0.90, df = 1 (P value = 0.34), I² = 0%).

#### Time to infusion/placement

Time to placement/start of infusion was reported by two trials (Slesak [@b17]; Spandorfer [@b18]). Insertion of the intravenous route took longer than the subcutaneous route in both trials, however a pooled estimate could not be calculated because of insufficient data (i.e. no variance estimates) presented in Spandorfer [@b18].

In Slesak [@b17], it took on average two minutes longer (MD 120.00 seconds, 95% CI -4.80 to 244.80; n = 96; P value = 0.06) to insert via the intravenous route (Analysis 2.4). In Spandorfer [@b18] (n = 148), the median time from first insertion attempt to start of infusion in the intravenous group was 11.8 minutes compared to 3.5 minutes in the subcutaneous group.

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings 2).

#### Average number of insertion attempts

The average number of insertion attempts was not directly measured by any of the trials. However, [@b14] (n = 60) reported that 41 cannulae were used in the intravenous group compared to 34 in the subcutaneous group.

#### Dislodgement of device during infusion

One trial reported the number of dislodgements caused by patients pulling out the device (Duems [@b6]). Patients in the intravenous group were more likely to dislodge the device than those in the subcutaneous group (RR 3.78, 95% CI 1.16 to 12.34; n = 67; P value = 0.03) (Analysis 2.5).

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings 2).

#### Time with functional access

One trial measured the length of time in days before each cannula needed to be changed (Slesak [@b17]). There was no statistically significant difference observed between groups (MD 0.80 days, 95% CI -0.05 to 1.65; n = 96; P value = 0.07) (Analysis 2.6).

#### Local site reactions

See Analysis 2.7 and Analysis 2.8.

##### Any

The occurence of any local site reactions was reported by five trials ([@b2]; Challiner [@b3]; Harbo [@b8]; Selam [@b16]; Spandorfer [@b18]). There were fewer local site reactions in the intravenous group than in the subcutaneous group, although the difference was not statistically significant (RR 0.91, 95% CI 0.80 to 1.02; n = 247). There was substantial statistical heterogeneity between trials (Chi² P value \< 0.0001; I² = 58%).

###### Sensitivity analysis

There was a statistically significant reduced risk associated with the intravenous method when the analysis was restricted to the three trials with adequate allocation concealment (Challiner [@b3]; Harbo [@b8]; Spandorfer [@b18]) (RR 0.87, 95% CI 0.79 to 0.96; n = 202). There was no evidence of statistical heterogeneity between trials (Chi² P value = 0.30; I² = 17%).

##### Erythema

Erythema was reported by four trials (Challiner [@b3]; Harbo [@b8]; Slesak [@b17]; Spandorfer [@b18]). There were fewer cases of erythema in the intravenous group than in the subcutaneous group (RR 0.43, 95% CI 0.31 to 0.61; n = 296). There was substantial statistical heterogeneity between trials (Chi² P value \< 0.0001; I² = 63%).

###### Sensitivity analysis

The effect remained when we restricted the analysis to the three trials with adequate allocation concealment (Challiner [@b3]; Harbo [@b8]; Spandorfer [@b18]) (RR 0.33, 95% CI 0.22 to 0.49; n = 202). There was no statistical heterogeneity between trials (Chi² P value = 0.73; I² = 0%).

##### Swelling

Swelling was reported by one trial (Spandorfer [@b18]). There were fewer cases of swelling in the intravenous group than in the subcutaneous group (RR 0.26, 95% CI 0.17 to 0.41; n = 148).

##### Infection

Infection was reported by four trials (Delamaire [@b5]; Duems [@b6]; Harbo [@b8]; Slesak [@b17]). More patients in the intravenous group developed an infection (e.g. cellulitis and lymphangitis) compared to the subcutaneous group (RR 3.70, 95% CI 1.06 to 12.88; n = 211; P value = 0.04). There was no statistical heterogeneity between trials (Chi² P value = 0.37; I² = 6%).

###### Sensitivity analysis

There was no difference in the risk of infection between groups when we restricted the analysis to the one trial with adequate allocation concealment (Harbo [@b8]) (RR 3.00, 95% CI 0.14 to 65.16; n = 18; P value = 0.48).

##### Oedema

Oedema was reported by seven trials (Challiner [@b3]; Delamaire [@b5]; Duems [@b6]; Harbo [@b8]; [@b14]; Slesak [@b17]; Spandorfer [@b18]). Fewer patients in the intravenous group experienced oedema at the insertion site compared to those in the subcutaneous group (RR 0.42, 95% CI 0.25 to 0.72; n = 453; P value = 0.001). There was no statistical heterogeneity between trials (Chi² P value = 0.89; I² = 0%).

###### Sensitivity analysis

The effect was not statistically significant when we restricted the analysis to the three trials with adequate allocation concealment (Challiner [@b3]; Harbo [@b8]; Spandorfer [@b18]) (RR 0.25, 95% CI 0.06 to 1.15; n = 202; P value = 0.07). There was no statistical heterogeneity between trials (Chi² P value = 0.93; I² = 0%).

##### Phlebitis

Phlebitis was reported by three trials (Duems [@b6]; Harbo [@b8]; Slesak [@b17]). More patients in the intravenous group experienced phlebitis than in the subcutaneous group (RR 5.04, 95% CI 1.14 to 22.30; n = 181). There was no statistical heterogeneity between trials (Chi² P value = 0.93; I² = 0%).

###### Sensitivity analysis

The effect was not statistically significant when we restricted the analysis to the one trial with adequate allocation concealment (Harbo [@b8]) (RR 3.00, 95% CI 0.14 to 65.16; n = 18; P value = 0.48).

#### Clinician\'s perception of ease of administration

Slesak [@b17] measured doctors\' and nurses\' perceptions of the feasibility of each insertion method using a Likert-like scale. There was no difference between the perceived feasibility of the two methods when scored by either the nurses (MD 0.00, 95% CI -0.12 to 0.12; n = 87; P value = 1.00) or doctors (MD 0.00, 95% CI -0.14 to 0.14; n = 96; P value = 1.00) (Analysis 2.9).

In Spandorfer [@b18], clinicians were more likely to report that the intravenous access was difficult to perform than the subcutaneous access (RR 6.33, 95% CI 2.32 to 17.23; n = 148; P value = 0.0003) (Analysis 2.10).

#### Needlestick injuries

None of the trials reported data on this outcome.

#### Patient discomfort

##### Pain

Three trials reported the number of patients with pain associated with the parenteral access method (Harbo [@b8]; Slesak [@b17]; Spandorfer [@b18]). There is no evidence that the number of patients reporting pain differed between the intravenous and subcutaneous groups (RR 1.01, 95% CI 0.83 to 1.22; n = 262; P value = 0.94). There was no statistical heterogeneity between trials (Chi² P value = 0.33; I² = 9%) (Analysis 2.11). We downgraded the quality of the evidence to low, due to high risk of bias and imprecision arising from small sample sizes.

###### Sensitivity analysis

The lack of evidence for a difference remained when we restricted the analysis to the two trials with adequate allocation concealment (Harbo [@b8]; Spandorfer [@b18]) (RR 0.97, 95% CI 0.81 to 1.16; n = 166; P value = 0.77). There was evidence of statistical heterogeneity between trials (I² = 53%); however, it was not statistically significant (Chi² P value = 0.15) (Analysis 2.12).

###### Discomfort

In Slesak [@b17], patients were also asked to score the discomfort of the procedure (1 = very good to 6 = very bad). There was no difference in the patients\' scores between the two groups (MD 0.00, 95% CI -0.21 to 0.21; n = 54; P value = 1.00) (Analysis 2.13).

##### Agitation

Two trials reported the number of patients who were agitated (Duems [@b6]; [@b14]). Patients in the intravenous group were more likely to be agitated than those in the subcutaneous group (RR 1.84, 95% CI 1.26 to 2.70; n = 125; P value = 0.002). There was no statistical heterogeneity between trials (Chi² P value = 0.34; I² = 0%).

#### Mortality

Mortality was reported by two trials (Challiner [@b3]; Duems [@b6]). In Challiner [@b3], one patient in the subcutaneous group died on day two and in Duems [@b6], three patients (two in the intravenous group, one in the subcutaneous group) died in the first 72 hours. When we pooled the data there was no difference in the risk of death between groups (RR 1.04, 95% CI 0.18 to 5.92; n = 103; P value = 0.96). There was no statistical heterogeneity between trials (Chi² P value = 0.40; I² = 0%) (Analysis 2.14).

##### Sensitivity analysis

The lack of evidence for a difference in risk remained when we restricted the analysis to the one trial with adequate allocation concealment (Challiner [@b3]) (RR 0.37, 95% CI 0.02 to 8.53; n = 36; P value = 0.53) (Analysis 2.15).

#### Volume of fluid infused

The volume of fluid infused was reported by four trials (Duems [@b6]; [@b14]; Slesak [@b17]; Spandorfer [@b18]). Due to clinical heterogeneity we did not calculate a pooled estimate, although effect estimates from each trial are presented on a forest plot to provide a visual summary (Analysis 2.16). A larger volume of fluid was infused via the intravenous route in all but one trial.

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and inconsistency (Summary of findings 2).

##### Sensitivity analysis

There was no difference in the volume of fluid infused in the one trial with adequate allocation concealment (Spandorfer [@b18]) (MD 90.80 95% CI -63.55 to 245.15; n = 148; P value = 0.25).

#### Electrolyte levels

##### Sodium

Sodium level was reported by one trial (Slesak [@b17]). The mean sodium level was higher in the intravenous group (139 ± 5 mmol/l) compared to the subcutaneous group (137 ± 5 mmol/l), although the difference is not statistically significant (MD -2.00 mmol/l, 95% -0.24 to 4.24; n = 77; P value = 0.08) (Analysis 2.18).

##### Potassium

None of the trials reported data on this outcome.

#### Renal function

See Analysis 2.19.

##### Urea

Urea level was reported by one trial (Duems [@b6]). Urea levels were on average lower in the intravenous group than in the subcutaneous group, although the difference is not statistically significant (MD -11.29 mg/dL, 95% CI -24.69 to 2.11; n = 67; P value = 0.10).

##### Creatinine

Creatinine level was reported by two trials (Duems [@b6]; Slesak [@b17]). There was no difference in creatinine levels between the two groups (MD -0.08, 95% CI -0.33 to 0.16; n = 138; P value = 0.51). There was no statistical heterogeneity between trials (Chi² P value = 0.95; I² = 0%).

### Saphenous vein cutdown versus intraosseous access

This comparison was assessed by one cross-over trial (n = 13) (Hubble [@b10]).

#### Insertion failures

There were more failures when attempting saphenous vein cutdown than intraosseous access, although the difference was not statistically significant (RR 4.00, 95% CI 0.51 to 31.13; P value = 0.19) (Analysis 3.1).

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings 3).

#### Time to infusion/placement

On average it took about 3.5 minutes longer to achieve access by saphenous vein cutdown than intraosseous access (MD 219.60 seconds, 95% CI 135.44 to 303.76; P value \< 0.0001) (Analysis 3.2).

We rated the quality of the evidence as moderate according to GRADE, as we downgraded it for risk of bias (Summary of findings 3).

#### Average number of insertion attempts

The trial did not report data on this outcome.

#### Dislodgement of device during infusion

The trial did not report data on this outcome.

#### Time with functional access

This outcome was not relevant, as insertion attempts were on a cadaver.

#### Local site reactions

This outcome was not relevant, as both insertion attempts were on a cadaver.

#### Clinician\'s perception of ease/feasibility of access route

The trial did not report data on this outcome.

#### Needlestick injuries

The trial did not report data on this outcome.

#### Patient discomfort

This outcome was not relevant, as insertion attempts were on a cadaver.

#### Mortality

This outcome was not relevant, as insertion attempts were on a cadaver.

#### Volume of fluid infused

This outcome was not relevant, as insertion attempts were on a cadaver.

#### Electrolyte levels

This outcome was not relevant, as insertion attempts were on a cadaver.

#### Renal function

This outcome was not relevant, as insertion attempts were on a cadaver.

### Peripheral intravenous versus intraperitoneal access

This comparison was assessed by one cross-over trial (n = 6) (Selam [@b16]), which compared intravenous and intraperitoneal access for insulin infusion.

#### Insertion failures

The trial did not report data on this outcome.

#### Time to infusion/placement

The trial did not report data on this outcome.

#### Average number of insertion attempts

The trial did not report data on this outcome.

#### Dislodgement of device during infusion

The trial did not report data on this outcome.

#### Time with functional access

The trial did not report data on this outcome.

#### Local site reactions

One of the six patients suffered an obstructed catheter during the intravenous phase. No complications data were reported for the intraperitoneal group.

#### Clinician\'s perception of ease of administration

The trial did not report data on this outcome.

#### Needlestick injuries

The trial did not report data on this outcome.

#### Patient discomfort

Two of six patients suffered transient episodes of abdominal pain during the intraperitoneal phase. No pain data were reported for the intravenous group.

#### Mortality

The trial did not report data on this outcome.

#### Volume of fluid infused

This outcome was not relevant, as both trials involved the infusion of medication, not fluids for hydration.

#### Electrolyte levels

This outcome was not relevant, as both trials involved the infusion of medication, not fluids for hydration.

#### Renal function

This outcome was not relevant, as both trials involved the infusion of medication, not fluids for hydration.

### Intraperitoneal versus subcutaneous access

Two cross-over trials compared the intraperitoneal and subcutaneous routes for infusion of medications (Liebl [@b13]; Selam [@b16]).

#### Insertion failures

The trials did not report data on this outcome.

#### Time to infusion/placement

The trials did not report data on this outcome.

#### Average number of insertion attempts

The trials did not report data on this outcome.

#### Dislodgement of device during infusion

The trials did not report data on this outcome.

#### Time with functional access

The trials did not report data on this outcome.

#### Local site reactions

In Selam [@b16], all six patients experienced local reactions after three to four weeks of the subcutaneous phase, beginning with induration and inflammation at the insertion site before rejection of the catheter.

In Liebl [@b13], it is reported that 21% of patients in months one to six and 10% patients in months seven to 12 experienced local inflammation or infection during the intraperitoneal phase. The number of complications during the subcutaneous phase was not reported.

#### Clinician\'s perception of ease of administration

The trials did not report data on this outcome.

#### Needlestick injuries

The trials did not report data on this outcome.

#### Patient discomfort

In Selam [@b16], two of the six patients suffered transient episodes of abdominal pain during the intraperitoneal phase.

In Liebl [@b13], it is reported that 12% of patients in months one to six and 49% in months seven to 12 reported severe pain during the intraperitoneal phase.

#### Mortality

The trials did not report data on this outcome.

#### Volume of fluid infused

This outcome was not relevant, as both trials involved the infusion of medication not fluids for hydration.

#### Electrolyte levels

This outcome was not relevant, as both trials involved the infusion of medication not fluids for hydration.

#### Renal function

This outcome was not relevant, as both trials involved the infusion of medication not fluids for hydration.

### Reporting bias

There were insufficient data to produce funnel plots for any of the outcomes.

#### ADDITIONAL SUMMARY OF FINDINGS *\[Explanation\]*

**Intravenous versus subcutaneous route for achieving parenteral accessPatient or population:** adults or children requiring parenteral access for infusion of fluids or medication**Settings:** USA (children\'s unit) and Europe (older people care units)**Intervention:** intravenous route**Comparison:** subcutaneous route**OutcomesIllustrative comparative risks\* (95% CI)Relative effect(95% CI)No of participants(studies)Quality of the evidence(GRADE)CommentsAssumed riskCorresponding riskSubcutaneous routeIntravenous routeInsertion failures**Study populationRR 14.79(2.87 to 76.08)238(3 RCTs)⊕⊕⊕○MODERATE ^1,2^IV rate calculated based on an assumed rate with the subcutaneous route generated from correction for zero events (1.14 per 100)There were no insertion failures observed with the subcutaneous route in the studies17 per 100(3 to 76)**Time to infusion/placement**The mean time to placement/start of infusion in the subcutaneous group was 300 secondsThe mean time to placement/start of infusion in the IV group was 120 seconds longer (4.8 shorter to 244.8 longer)-96(1 RCT)⊕⊕⊕○LOW ^3,4^-**Dislodgement of device**Study populationRR 3.78(1.16 to 12.34)67(1 RCT)⊕⊕⊕○LOW ^3,4^-9 per 10034 per 100(10 to 100)**Needlestick injuries**No studies reported this outcomeNo studies reported this outcome-NANA-**Volume of fluid infused**There was variation in the amount of fluid administered between trials, therefore we did not pool data. The size and direction of the effects differed across the 4 studies reporting data for this outcome-(4 RCTs)⊕⊕⊕○LOW ^3,5^-\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).CI: confidence interval; IV: intravenous; NA: not applicable; RCT: randomised controlled trial; RR: risk ratioGRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate.[^7][^8][^9][^10][^11]

**Saphenous vein cutdown versus intraosseous route for achieving parenteral accessPatient or population:** trainee paramedics using both methods of gaining parenteral access on cadavers**Settings:** USA (training laboratory)**Intervention:** saphenous vein cutdown**Comparison:** intraosseous**OutcomesIllustrative comparative risks\* (95% CI)Relative effect(95% CI)No of participants(studies)Quality of the evidence(GRADE)CommentsAssumed riskCorresponding riskIntraosseousSaphenous vein cutdownInsertion failures**Study populationRR 4(0.51 to 31.13)13(1 RCT)⊕⊕⊕○LOW ^1,2^-77 per 1000308 per 1000(39 to 2395)**Time to infusion/placement**Analysed as generic inverse variance outcome type. Difference between means was 219.6 seconds longer with saphenous vein cutdown (155.09 longer to 284.11 longer)-13(1 RCT)⊕⊕⊕○MODERATE ^1^-**Dislodgement of device**No studies reported this outcomeNo studies reported this outcome-NANA-**Needlestick injuries**No studies reported this outcomeNo studies reported this outcome-NANA-**Volume of fluid inserted**No studies reported this outcomeNo studies reported this outcome-NANA-\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). CI: confidence interval; NA: not applicable; RCT: randomised controlled trial; RR: risk ratioGRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate.[^12][^13]

Discussion
==========

Summary of main results
-----------------------

Evidence from randomised controlled trials suggests that intraosseous access may be achieved more rapidly and with fewer insertion failures than intravenous access. Subcutaneous access is also associated with fewer insertion failures than intravenous access. Taken together the evidence suggests that intraosseous and subcutaneous access are viable alternatives to peripheral intravenous access when the latter cannot be achieved. However, when inserted successfully, more fluid can be infused by the intravenous route than by either the intraosseous or subcutaneous route.

Only one small trial involving insertion of parenteral access into manikins explored the effect of personal protective equipment (PPE), thus there is insufficient evidence to determine reliably whether or not the use of PPE impacts on the merits of the different approaches. Also, there is insufficient evidence to draw any inferences about the relative merits of intraperitoneal access compared to other methods and there are no trials involving central intravenous access.

A particularly important consideration in the context of patients with Ebola virus disease (EVD) may be the likelihood of dislodgement of the parenteral access device during use. Two trials, one comparing intravenous with intraosseous access and one comparing intravenous with subcutaneous access, recorded the number of dislodgements. However, both were inadequately powered and were at risk of bias for important quality domains. They therefore do not provide reliable evidence on this important outcome so we are unable to draw any firm conclusions. There are also insufficient data to determine whether the intravenous route is associated with an increased or decreased risk of adverse events when compared to intraosseous access. When compared to subcutaneous access, intravenous access appears to cause less erythema, but more infection and phlebitis. However, the difference between the two methods in the risk of infection and phlebitis was not statistically significant when we restricted these analyses to trials with adequate allocation concealment. As expected given the nature of the insertion, subcutaneous infusion was associated with an increased risk of oedema and swelling.

Overall completeness and applicability of evidence
--------------------------------------------------

The included trials were conducted in a variety of clinical contexts involving a broad range of patient groups. Despite this we judged them to be sufficiently clinically homogenous to allow pooled analyses for most outcomes. As we anticipated at the protocol stage, none of the included trials were conducted in the context of EVD or a similar medical emergency. However, we judge that the advantages and disadvantages of the different parenteral methods observed in other clinical settings are likely to be similar in the context of EVD. If a trial, or a meta-analysis of all relevant trials, shows that a particular intervention increases or decreases the probability of a given outcome in one group of patients, we have to consider what effect it might have in another group of patients. Some people believe that an intervention should only be used in patients similar to those included in the trial (or trials) that showed the intervention to be effective. We believe that this view is naive. To generalise trial results properly we have to consider the mechanism by which the intervention affected the outcome and the factors that might be relevant to this mechanism. The results of this systematic review suggest that insertion of intraosseous access may be less likely to fail and may be quicker than the intravenous method. Would this also be the case in patients with EVD? Patients with EVD are often severely dehydrated due to severe gastrointestinal fluid losses. In such patients, we might reasonably expect that securing intravenous access would be even more difficult. Healthcare workers treating patients with EVD must wear personal protective equipment and often wear two or even three layered pairs of protective gloves. This would be expected to reduce their ability to palpate a vein, which would again make securing intravenous access more difficult. On the other hand, dehydration and health worker dexterity are less important for intraosseous access. For this reason, we would expect that securing intraosseous access would usually be quicker and easier than securing intravenous access in patients with EVD.

Quality of the evidence
-----------------------

We judged few trials to be at low risk of bias for any of the assessed domains. Of particular concern is the small number of trials (n = 3) that used adequate allocation concealment. Where possible we explored the influence of trials with unclear or high risk of bias for allocation concealment using sensitivity analyses. Blinding was not feasible due to the nature of the interventions and this may have introduced bias, particularly in the assessment of subjective outcomes. In some trials, attrition between groups might also have introduced bias. For example, in Banerjee [@b1] 10 patients (30%) allocated to the intravenous group were switched to the intraosseous group because venous access could not be achieved. It is possible that these patients were more dehydrated, which might account for the difficulty with venous access. As the trial data were not presented on an intention-to-treat basis, a favourable effect of intraosseous access on outcomes may have been diluted.

Also, because the estimated information size for the meta-analysis (n = 1388) was not achieved for the primary outcome (insertion failures) for any of the routes compared, we cannot discount the possibility that the observed increase in risk of insertion failure associated with the intravenous method compared to both the intraosseous and subcutaneous methods are false positives, although the P values accompanying the pooled effect estimates are very small (≤ 0.001).

Potential biases in the review process
--------------------------------------

As with all systematic reviews, publication and reporting biases should be considered as potential threats to the validity of the findings of this review. We undertook comprehensive searching but cannot discount the possibility that trials, in particular unpublished trials, were not identified.

Also, few trials contributed data to each outcome, which may suggest some selective outcome reporting. Indeed, comparison of prespecified outcomes with those given in the final report for the one trial that was prospectively registered, did suggest selective outcome reporting. However, this could not be explored for the other included trials, which had not been prospectively registered. We were also unable to explore the presence of reporting bias using funnel plots because there were too few trials included in the meta-analyses.

Two trials reported data for some continuous outcomes as medians and ranges (Reades [@b15]; Slesak [@b17]). To allow these data to be included in the meta-analyses, we estimated the corresponding means and standard deviations using the approach described in Hozo [@b40]. However, meta-analysis of the difference in means is appropriate, assuming that the data are normally distributed. That these data were presented as medians and ranges may indicate that their distributions were skewed and not normally distributed. The estimates of the mean difference based on these data should therefore be interpreted with caution.

Agreements and disagreements with other studies or reviews
----------------------------------------------------------

The findings of this systematic review are largely consistent with those of other relevant literature reviews. We identified two other reviews that summarised the results of observational and intervention studies assessing the use of subcutaneous infusion for treating dehydration in older adults (Remington [@b43]; Rochon [@b45]). The conclusion of both reviews was that subcutaneous infusion is a safe and feasible alternative to intravenous fluid administration for treating mild to moderate dehydration in the elderly.

Another article reported the results of a systematic review of observational and intervention studies assessing the effectiveness of non-oral and non-intravenous methods for treating dehydration in children (Rouhani [@b46]). The authors noted the lack and limited quality of the evidence, but concluded that the intraosseous method could be an effective alternative when intravenous access is not feasible. Although they noted promising results from case series studies, they also concluded that there was insufficient evidence to recommend the intraperitoneal or subcutaneous method above other parenteral access methods in this patient group.

Authors\' conclusions
=====================

Implications for practice
-------------------------

There are several different ways of achieving parenteral access in patients who are unable to meet their fluid requirements enterally. In view of the large number of cases and the severe resource constraints, methods for achieving parenteral access in the context of Ebola virus disease (EVD) need to be simple, easy and quick, and must not put healthcare workers at unnecessary risk. The quality of the evidence in this review is somewhat limited, largely because of the lack of adequately powered trials at low risk of bias. Although this prevents us from drawing firm conclusions regarding the magnitude of the difference between parenteral access methods, useful inferences about the likely direction of effects can be made for some outcomes.

The choice of method used in clinical practice may depend on site-specific issues such as the availability and expertise of medical and nursing staff, patient numbers and local infrastructure. If intravenous access can be achieved easily, this facilitates the infusion of larger volumes of fluid and also allows blood samples to be drawn for testing (e.g. for EVD or malaria) at the time of insertion. However, if this is not possible, intraosseous and subcutaneous routes are alternatives that can be achieved rapidly. The subcutaneous route may be suitable for patients who are not severely dehydrated but in whom ongoing fluid losses cannot be met by oral intake. Given the ease of insertion of subcutaneous lines, they could be inserted by healthcare workers with minimal medical training.

It is expected that most clinicians are familiar with the intravenous method, but may be less so with the other methods although these can be easily taught.

A film to accompany this review can be viewed here.

Implications for research
-------------------------

The quality of the included trials was low. Further comparative trials of alternative approaches are appropriate if those caring for patients with EVD remain uncertain about which is the most effective strategy for securing reliable parenteral access. Importantly, there is no reliable information on the extent to which the different parenteral access devices are dislodged during use. This might be particularly relevant in the context of the current epidemic of EVD, where there are shortages of nursing and medical staff, since the volume of fluid administered might depend on the duration of parenteral access. Also, there is a lack of data on the impact of personal protective equipment on parenteral access methods and whether effects differ in children, which should be addressed by future trials. There are no data on the relative merits of intraperitoneal access. This method has been used to resuscitate severely dehydrated infants with cholera in whom achieving intravenous access is difficult (Mahalanabis [@b25]). Whether it is more effective than intravenous, intraosseous or subcutaneous access remains unknown. Future trials should be prospectively registered, have secure allocation concealment, adequate sample sizes and should be reported according to established standards.

We are grateful for feedback from the anonymous peer referees. We acknowledge the support and assistance from the Cochrane Editorial Unit, especially Toby Lasserson. We also thank Monica Arribas and Emma Sydenham for help with the translation of non-English language articles.

Appendix 1. Search strategies
=============================

**Cochrane Injuries Group Specialised Register & Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library)**

\#1((Intravenous or venous) ADJ3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)):TI,AB,KY

\#2MESH DESCRIPTOR Infusions, Intravenous

\#3\#1 OR \#2

\#4((intraperitoneal\*) ADJ3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or hydrat\* or rehydrat\* or drug\* or medication\*)):TI,AB,KY

\#5MESH DESCRIPTOR Infusions, Intraosseous

\#6(intraosseous\*) ADJ3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)

\#7\#5 OR \#6

\#8MESH DESCRIPTOR Infusions, Subcutaneous

\#9MESH DESCRIPTOR Hypodermoclysis

\#10((subcutaneous\* or hypodermoclysis) ADJ3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)):TI,AB,KY

\#11\#8 OR \#9 OR \#10

\#12\#4 OR \#7 OR \#11

\#13\#3 AND \#12\#

14\#3 OR \#7 OR \#11

\#15\#4 AND \#14

\#16\#3 OR \#4 OR \#11

\#17\#7 AND \#16

\#18\#3 OR \#4 OR \#7

\#19\#11 AND \#18

\#20\#13 OR \#15 OR \#17 OR \#19

\#21\* NOT INMEDLINE NOT INEMBASE

\#22\#20 AND \#21

**Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R)**

1\. Infusions, Intravenous/

2\. ((\"intra?venous\*\" or venous) adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)).ab,ti.

3\. 1 or 2

4\. (\"intra?peritoneal\*\" adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or hydrat\* or rehydrat\* or drug\* or medication\*)).ab,ti.

5\. Infusions, Intraosseous/

6\. (\"intra?osseous\*\" adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)).ab,ti.

7\. 5 or 6

8\. infusions, subcutaneous/ or hypodermoclysis/

9\. ((subcutaneous\* or subcut or hypodermoclysis) adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)).ab,ti.

10\. 8 or 9

11\. 4 or 7 or 10

12\. 3 and 11

13\. 3 or 7 or 10

14\. 4 and 13

15\. 3 or 4 or 10

16\. 7 and 15

17\. 3 or 4 or 7

18\. 10 and 17

19\. 12 or 14 or 16 or 18

20\. randomi?ed.ab,ti.

21\. randomized controlled trial.pt.

22\. controlled clinical trial.pt.

23\. placebo.ab.

24\. clinical trials as topic.sh.

25\. randomly.ab.

26\. trial.ti.

27\. Comparative Study/

28\. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27

29\. (animals not (humans and animals)).sh.

30\. 28 not 29

31\. 19 and 30

**Embase + Embase Classic**

1\. Infusions, Intravenous/

2\. ((\"intra?venous\*\" or venous) adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)).ab,ti.

3\. 1 or 2

4\. (\"intra?peritoneal\*\" adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or hydrat\* or rehydrat\* or drug\* or medication\*)).ab,ti.

5\. Infusions, Intraosseous/

6\. (\"intra?osseous\*\" adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)).ab,ti.

7\. 5 or 6

8\. infusions, subcutaneous/ or hypodermoclysis/

9\. ((subcutaneous\* or subcut or hypodermoclysis) adj3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)).ab,ti.

10\. 8 or 9

11\. 4 or 7 or 10

12\. 3 and 11

13\. 3 or 7 or 10

14\. 4 and 13

15\. 3 or 4 or 10

16\. 7 and 15

17\. 3 or 4 or 7

18\. 10 and 17

19\. 12 or 14 or 16 or 18

20\. exp Randomized Controlled Trial/

21\. exp controlled clinical trial/

22\. exp controlled study/

23\. comparative study/

24\. randomi?ed.ab,ti.

25\. placebo.ab.

26\. \*Clinical Trial/

27\. exp major clinical study/

28\. randomly.ab.

29\. (trial or study).ti.

30\. 20 or 21 or 22 or 24 or 25 or 26 or 27 or 28 or 29

31\. exp animal/ not (exp human/ and exp animal/)

32\. 30 not 31

33\. 19 and 32

34\. limit 33 to exclude medline journals

**CINAHL Plus (EBSCO)**

S1(MH \"Clinical Trials\")S2PT clinical trial\*S3TX clinical N3 trial\*S4TI ( (singl\* N3 blind\*) or (doubl\* N3 blind\*) or (trebl\* N3 blind\*) or (tripl\* N3 blind\*) ) or TI ( (singl\* N3 mask\*) or (doubl\* N3 mask\*) or (trebl\* N3 mask\*) or (tripl\* N3 mask\*) ) or AB ( (singl\* N3 blind\*) or (doubl\* N3 blind\*) or (trebl\* N3 blind\*) ) or AB ( (singl\* N3 mask\*) or (doubl\* N3 mask\*) or (trebl\* N3 mask\*) or (tripl\* N3 mask\*) )S5TX randomi?ed N3 control\* N3 trial\*S6(MH \"Placebos\")S7TX placebo\*S8(MH \"Random Assignment\")S9TX random\* N3 allocat\*S10MH quantitative studiesS11S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10S12(MH \"Infusions, Intravenous\")S13TI (intravenous N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*))S14AB (intravenous N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*))S15S12 OR S13 OR S14S16TI intraperitoneal\*\" N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or hydrat\* or rehydrat\* or drug\* or medication\*)S17AB intraperitoneal\*\" N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or hydrat\* or rehydrat\* or drug\* or medication\*)S18S16 OR S17S19(MH \"Infusions, Intraosseous\")S20TI intraosseous\* N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)S21AB intraosseous\* N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)S22S19 OR S20 OR S21S23(MH \"Infusions, Subcutaneous\")S24(MH \"Hypodermoclysis\")S25TI (subcutaneous\* or hypodermoclysis) N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)S26AB (subcutaneous\* or hypodermoclysis) N3 (route\* or access\* or insert\* or device\* or method\* or fluid\* or therap\* or administer\* or administrat\* or infus\* or dehydrat\* or rehydrat\* or hydrat\* or drug\* or medication\*)S27S23 OR S24 OR S25 OR S26S28S18 OR S22 OR S27S29S15 AND S28S30S15 OR S22 OR S27S31S18 AND S30S32S15 OR S18 OR S27S33S22 AND S32S34S15 OR S18 OR S22S35S27 AND S34S36S29 OR S31 OR S33 OR S35S37S11 AND S36 Limiters - Exclude MEDLINE records

**Clinicaltrials.gov**

( subcutaneous OR rectal OR proctoclysis OR intraosseous ) AND INFLECT EXACT \"Interventional\" \[STUDY-TYPES\] AND fluids \[TREATMENT\]

**Estimation of mean**

If sample size is = 25, median can be used to estimate mean.

**Estimation of standard deviation (SD)**

If moderate sample size (15 \< n ≤ 70) estimated SD = range/4.

If large sample size (n = 70) estimated SD = range/6.

(Hozo [@b40]).
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
=======================================

We added further details to the Types of studies and Types of participants sections. These changes do not represent a change in the inclusion criteria between the protocol and review, but have been made based on the recommendations in editorial comments on the completed review to improve clarity.

We have included a paragraph to describe how data from cluster-randomised controlled trials would be included in the analysis.

At the request of the Cochrane Editorial Unit editors, we refined the outcomes included in the \'Summary of findings\' tables and GRADE assessment. Rather than including all outcomes as originally proposed, only outcomes most closely aligned with the objectives of the review are included (success of route of placement; time to placement/start of infusion; dislodgement of device during infusion; volume of fluid infused and needlestick injuries).

Characteristics of studies
==========================

Characteristics of included studies *\[ordered by study ID\]*
-------------------------------------------------------------

Banerjee 1994MethodsParallel randomised trialParticipantsSetting: hospital emergency unit in Chandigarh, India 60 children (aged 3 months to 2 years) with severe dehydration due to diarrhoea and/or vomiting • Intravenous group: (n = 30); M/F = NR; mean age (SEM) = 8.6 (1.6) months • Intraosseous group: (n = 30); M/F = NR; mean age (SEM) = 8.9 (2.0) monthsInterventions• Intravenous group: 22 or 24 G Teflon catheter, insertion site not specified • Intraosseous group: 18 G spinal needle with stylet or 16 to 18 G hypodermic needle with stylet, insertion site not specified Both groups were infused with normal saline and/or N/2 saline in 5% dextrose with potassium 20 mEQ/L, if not contraindicated Insertions were performed by paediatric residents with 1 year of clinical experienceOutcomesFailure of route placement\^, defined as failure to secure route within 5 minutes of first attempt Time taken to secure access° Serum sodium° Serum potassium° Urea° Creatinine° *\^data analysed as intention-to-treat* °*data analysed as-treated*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskParticipants were \"assigned alternately\"Allocation concealment (selection bias)High riskParticipants were \"assigned alternately\"Blinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the effect estimate would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesLow riskWe judge that measurement of these outcomes is not likely to be influenced by lack of blindingBlinding of outcome assessment (detection bias) Subjective outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionHigh riskAccess could not be secured in 10 patients in the IV group who were switched to the IO group. Data on success of insertion were included in the meta-analysis on an intention-to-treat basis. Time for insertion data were presented and are therefore included in the meta-analysis according to route receivedIncomplete outcome data (attrition bias) Clinical outcomesHigh riskData presented and therefore included in the meta-analysis according to the route receivedIncomplete outcome data (attrition bias) Subjective outcomesUnclear riskData on these outcomes were not reportedSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Boullu-Sanchis 2006MethodsParallel randomised trialParticipantsSetting: diabetology department, France 37 patients hospitalised for uncontrolled type 2 diabetes • Intravenous group: (n = 13); M/F = 8/5; mean age (SD) = 57.9 (2.6) • Subcutaneous group: (n = 20); M/F = 9/11; mean age (SD) = 59.0 (1.5)Interventions• Intravenous group: pump continuously administered solution of 0.4 ml regular insulin in 39.6 ml saline • Subcutaneous group: continuous infusion with intermittent bolus. Site changed every 3 days Unclear who performed the insertionsOutcomesLocal site reactions*\^* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskDescribed as \"randomized by drawing to either group 1 or group 2\"Allocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Subjective outcomesLow risk4 patients (2 in each group) were excluded, however we judged that the reasons for the missing data are unlikely to be related to outcomeSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Challiner 1994MethodsParallel randomised trialParticipantsSetting: elderly care unit, UK 34 elderly stroke patients requiring parenteral nutrition because of impaired consciousness or dysphagia • Intravenous group: (n = 17); M/F = 6/11; mean age (range) = 84.2 (71 to 95) years • Subcutaneous group: (n = 17); M/F = 6/11; mean age (range) = 82.8 (69 to 93) yearsInterventions• Intravenous group: details of route not described • Subcutaneous group: 10 G butterfly cannula sited on the trunk, axillary, scapular or thigh area. 1500 units of hyaluronidase added to each bag if infusion ran behind time Both groups infused with 2 litres of isotonic dextrose--saline per 24 hours over 3 days Unclear who performed the insertionsOutcomesLocal site reactions*\^* Mortality*\^* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generatedAllocation concealment (selection bias)Low riskSequentially numbered, sealed envelopesBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesLow riskWe judge that measurement of these outcomes is not likely to be influenced by lack of blindingBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionHigh risk2 patients allocated to the subcutaneous group were excluded from the trial analysis - 1 died and 1 developed local oedemaIncomplete outcome data (attrition bias) Clinical outcomesLow riskData for the patient in the subcutaneous group excluded from the trial analysis have been included in the meta-analysis for the mortality outcomeIncomplete outcome data (attrition bias) Subjective outcomesLow riskData for the patient in the subcutaneous group excluded from the trial analysis have been included in the meta-analysis for the local site reactions (oedema) outcomeSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Dardaine 1995MethodsRandomised cross-over trialParticipantsSetting: hospital, France 6 hospitalised, elderly patients who had been admitted at least 45 days before, for rehabilitation after a bone trauma requiring surgery M/F = 1/5; mean age (SD) = 81.5 (9.8) yearsInterventions• Intravenous group: administered into forearm vein • Subcutaneous group: administered into the anterior wall of the abdomen Both groups infused with 1000 ml of 5% glucose solution containing 4 g NaCl over 6 hours Unclear who performed the insertionsOutcomesNone of interest to this reviewNotes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskData on this outcome were not reportedBlinding of outcome assessment (detection bias) Subjective outcomesUnclear riskData on this outcome were not reportedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskNo exclusions describedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on this outcome were not reportedIncomplete outcome data (attrition bias) Subjective outcomesUnclear riskData on this outcome were not reportedSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Delamaire 1992MethodsParallel randomised trialParticipantsSetting: hospital, France 30 elderly patients (average 83 years) requiring rehydration (unable to take sufficient oral hydration) • Intravenous group: (n = 15); M/F = 6/11; mean age (SD) = NR • Subcutaneous group: (n = 15); M/F = NR; mean age (SD) = NRInterventions• Intravenous group: • Subcutaneous group: Both groups infused with 1 litre solution of 2.5% glucose + 4.5g sodium chloride Unclear who performed the insertionsOutcomesFailures of route replacement*\^*, definition of failure not described Local site reactions (oedema, infection)*\^* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskNo exclusionsIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Subjective outcomesLow riskNo exclusionsSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Duems Noriega 2014MethodsParallel randomised trialParticipantsSetting: hospital, Spain 70 patients with mild to moderate dehydration and oral intolerance, aged 65 years and older, admitted to hospital • Intravenous group: (n = 33); M/F = 20/14; mean age (SD) = 84.3 (6.6) years • Subcutaneous group: (n = 34); M/F = 15/18; mean age (SD) = 86.4 (8.5) yearsInterventions• Intravenous group: administered through catheters sited at back of the hand, forearm or inner elbow, avoiding previously damaged areas • Subcutaneous group: 21 to 25 G needles sited at inside of the thighs, lateral abdominal wall or the scapular region, avoiding previously damaged areas Both groups infused up to 1.5 litres per 24 hours of either NaCl 0.9% or glucose 5% or mixed solution (saline 0.45% + glucose 5%). 20 mEq of potassium chloride could be added per litre Unclear who performed the insertionsOutcomesDislodgements*\^* Local site reactions (oedema, infection)*\^* Mortality*\^* Patient discomfort (agitation)*\^* Volume of fluid infused*\^* Creatinine*\^* Urea*\^* *\^data analysed as intention-to-treat*NotesTrial report in Spanish***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskRandomisation by mixed blocks of 6 sealed envelopes. Each block with 3 cards with the treatment IV and 3 with SCBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesLow riskWe judge that measurement of these outcomes is not likely to be influenced by lack of blindingBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionHigh risk3 patients who died during the study period were excluded from the trial analysisIncomplete outcome data (attrition bias) Clinical outcomesHigh riskData for the 3 patients (2 in the intravenous group, 1 in the subcutaneous group) who died during the study period were excluded from the trial analysis. These data have been included in the meta-analysis for the mortality outcome. However, risk of bias remains for renal function outcomesIncomplete outcome data (attrition bias) Subjective outcomesHigh risk3 patients who died during the study period were excluded from the trial analysisSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Harbo 2009MethodsRandomised cross-over trialParticipantsSetting: Aarhus University Hospital, Denmark 10 intravenous immunoglobulin responsive patients with multifocal motor neuropathy M/F = 4/5; mean age (SD) = 49.2 (10.51) yearsInterventions• Intravenous group: administered during hospital admission through a permanent IV catheter inserted into the subclavian vein (n = 2) or peripheral vein (n = 7) • Subcutaneous group: syringe pump and butterfly needle into tissue at the abdominal wall. Received 80 to 155 ml at 4 to 8 injection sites each week at an infusion time of 2 to 4 hours Both groups infused with immunoglobulin Unclear who performed the IV insertions; SC insertions performed initially by nurse and then were self administeredOutcomesLocal site reactions (erythema, oedema, infection)*\^*ˤ Pain*\^*ˤ (how this was assessed is not described in the report) *\^data analysed as intention-to-treat* ˤ*data included in review as a parallel trial; this approach leads to a unit of analysis error, causing the CIs to be too wide and the trial to receive too little weight*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Low riskPharmacy-controlledBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Subjective outcomesLow riskNo post-randomisation exclusionsSelective reporting (reporting bias)Unclear riskRegistered after start of recruitment (NCT00268788). Adverse events listed as a secondary outcomes Harvey 1987MethodsRandomised cross-over trialParticipantsSetting: London, UK 9 patients with malignant disease M/F = NR; mean age (SD) = NRInterventions• Intravenous group: into forearm vein via Teflon catheter • Subcutaneous group: into anterior abdominal wall via 25 G steel needle 15 mg bleomycin in saline with 100 mg hydrocortisone Unclear who performed the insertionsOutcomesLocal site reactions, although insufficient data presented for meta-analysisNotes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Subjective outcomesUnclear riskNo exclusions reported, although presented data were insufficient for meta-analysisSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Hubble 2001MethodsRandomised cross-over trialParticipantsSetting: hospital training laboratory, USA 13 students of the senior class of baccalaureate degree paramedical programme, recently trained in both methods M/F = NR; mean age (SD) = NRInterventions• Saphenous vein cutdown: at the ankle in a cadaver using standard technique with insertion of an IV cannula under direct visualisation • Intraosseous group: using the BIG® into the proximal tibia of a cadaver Both access routes connected to a 1000 ml bag of NaCl solution Insertions performed by members of senior class of a baccalaureate degree paramedical programmeOutcomesFailure of route placement*\^*ˤ (defined as inability to initiate fluid flow) Time to infusion*\^* *\^data analysed as intention-to-treat* ˤ*data included in review as a parallel trial; this approach leads to a unit of analysis error, causing the CIs to be too wide and the trial to receive too little weight*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (simulated using a cadaver)Blinding of outcome assessment (detection bias) Subjective outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskNo exclusionsIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskNot applicable (simulated using a cadaver)Incomplete outcome data (attrition bias) Subjective outcomesLow riskNo exclusionsSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Hägglund 1998MethodsParallel randomised trialParticipantsSetting: Huddinge Hospital, Sweden 38 adult patients receiving bone marrow transplants from related donor • Intravenous group: (n = 20); M/F = NR; median age (range) = 38 (19 to 54) years • Intraosseous group: (n = 9); M/F = NR; median age (range) = 38 (20 to 50) yearsInterventions• Intravenous group: details of route not described • Intraosseous group: 2 bone marrow aspiration needles inserted into each side of the posterior iliac crests under local anaesthesia. Infusion given with or without overpressure using a 50 cc syringe Both groups infused with bone marrow Unclear who performed the insertionsOutcomesLocal site reactions (infection)ʶ ʶdata not analysed on an intention-to-treat basis; data on patient who switched treatment excluded from trial analysisNotes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Incomplete outcome data (attrition bias) Subjective outcomesHigh riskApparent from the report that 1 patient in the IO group switched to receive half the volume as an IV infusion because of severe pain and was excluded from the analysisSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Lamhaut 2010 (no PPE)MethodsRandomised cross-over trialParticipantsSetting: pre-hospital department of a hospital, France 25 pre-hospital emergency professionals (9 nurses and 16 physicians) M/F = NR; mean age (SD) = NRInterventions• Intravenous group: single-use 18 G peripheral intravenous catheter inserted into a training manikin • Intravenous group + CBRN: as above while wearing CBRN protective equipment • Intraosseous group: using EZ-IO® 15 G needle inserted into training manikin • Intraosseous group + CBRN: as above while wearing CBRN protective equipment Both access routes connected to bag of fluid solution Insertions performed by pre-hospital emergency professionals (9 nurses and 16 physicians)OutcomesInsertion failures*\^*, not clearly defined, described only as \"failure of an IV or IO access attempt, including the case of absence of fluid after connection of the infusion line to the vascular access\" Time to infusion*\^* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated randomisationAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (simulated using manikin)Blinding of outcome assessment (detection bias) Subjective outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskNo exclusionsIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskNot applicable (simulated using a manikin)Incomplete outcome data (attrition bias) Subjective outcomesUnclear riskData on these outcomes were not reportedSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Lamhaut 2010 (with PPE)MethodsRandomised cross-over trialParticipantsSetting: pre-hospital department of a hospital, France 25 pre-hospital emergency professionals (9 nurses and 16 physicians) M/F = NR; mean age (SD) = NRInterventions• Intravenous group + CBRN: as above while wearing CBRN protective equipment • Intraosseous group + CBRN: as above while wearing CBRN protective equipment Both access routes connected to bag of fluid solutionOutcomesInsertion failures*\^*, not clearly defined, described only as \"failure of an IV or IO access attempt, including the case of absence of fluid after connection of the infusion line to the vascular access\" Time to infusion*\^* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated randomisationAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskNo exclusionsIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Incomplete outcome data (attrition bias) Subjective outcomesUnclear riskData on these outcomes were not reportedSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Liebl 2009MethodsRandomised cross-over trialParticipantsSetting: centres in Netherlands, France, Austria, Germany and Switzerland 61\* patients with type 1 diabetes with frequent hypoglycaemia and/or HbA1c = 7.0% M/F = 44/16; mean age (SD) = 50.5 (10.8) years (\*1 patient excluded)Interventions• Intraperitoneal: using the DiaPort system, implanted under general anaesthesia into the subcutaneous tissue of the abdominal wall. Insulin is infused into the abdominal cavity • Subcutaneous group: continuous infusion of insulin lispro Unclear who performed the insertionsOutcomesLocal site reactions (infections and inflammations)° Pain° (how this was assessed is not described in the report) °*data analysed as-treated*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Incomplete outcome data (attrition bias) Subjective outcomesHigh riskLarge number of dropouts during study - 15 IP patients and 9 SC patients dropped out during first treatment period followed by 9 IP patients and 3 SC patients during the second treatment periodSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement O\'Keeffe 1996MethodsParallel randomised trialParticipantsSetting: acute geriatric unit, UK 60 elderly patients with cognitive impairment judged to require parenteral fluids for at least 48 hours because of mild dehydration or poor oral intake • Intravenous group: (n = 30); M/F = 13/17; mean age (SD) = 84 (7) years • Subcutaneous group: (n = 30); M/F = 10/20; mean age (SD) = 81 (6) yearsInterventions• Intravenous group: administered through an 18 or 20 G cannula in forearm vein • Subcutaneous group: administered in the infraclavicular, scapular, abdominal or thigh areas through a 21 G butterfly cannula Up to 2 litres of any combination of 0.9% normal saline, 0.45% normal saline and 5% dextrose Unclear who performed the insertionsOutcomesLocal site reactions (oedema)ʶ Patient discomfort (agitation related to cannula or drip)ʶ Volume of fluids infusedʶ ʶ*data not analysed on an intention-to-treat basis; data on patient who switched treatment excluded from trial analysis*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom numbers tableAllocation concealment (selection bias)Unclear riskSealed envelopesBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesHigh risk2 patients were excluded from the trial analyses (1 IV patient was switched to SC fluids and 1 patient in the SC group died). However, the mortality data were included in the meta-analysisIncomplete outcome data (attrition bias) Subjective outcomesHigh risk2 patients were excluded from the trial analyses (1 IV patient was switched to SC fluids and 1 patient in the SC group died)Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Reades 2011MethodsParallel randomised trialParticipantsSetting: pre-hospital setting in North Carolina, USA 182 adult patients with non-traumatic out-of-hospital cardiac arrest • Intravenous group: (n = 67); M/F = 42/25; mean age (SD) = 64.7 (2.2) years • Intraosseous group 1: (n = 51); M/F = 36/15; mean age (SD) = 61.2 (2.4) years • Intraosseous group 2: (n = 64); M/F = 41/23; mean age (SD) = 66.9 (2.1) yearsInterventions• Intravenous group: inserted into any accessible peripheral vein but preferably at the antecubital fossa • Intraosseous group 1: inserted into proximal humerus defined as the greater tubercle of the anterior humeral head 1 cm proximal to the surgical neck of humerus using EZ-IO® • Intraosseous group 2: inserted into the proximal tibia located medial to the tibial tuberosity, or just below the patella along the flat aspect of the tibia using EZ-IO® Data for intraosseous groups 1 and 2 were combined for the purpose of meta-analysis Insertions performed by paramedicsOutcomesFailure of route placement*\^* (\'first-attempt\' success was defined for IO insertion as secure placement of the catheter within the bone cavity and for IV insertion as secure placement within a peripheral vein. If initial access was not successful, the paramedics used their own judgement for choosing the subsequent site) Time taken to secure access‡*\^* Average number of insertion attempts\*‡*\^* Dislodgements of access method\**\^* Paramedics\' reported comfort with insertion method\**\^* Volume of fluid infused‡*\^* \**not specified in trial registration record* ‡*mean and SD estimated from reported median and IQR for analysis - moderate sample size therefore SD calculated as* = *range/4* *\^data analysed as intention-to-treat*NotesPrior to the study, all paramedics were trained on IO insertions using EZ-IO® on a human cadaver***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)High risk300 note cards were prepared in advance and labelled with a vascular access method. Each note card was sealed in a blank, numbered envelope. Each crew randomly selected and opened an envelope prior to every shift. The route selected was applied to the crew\'s first cardiac arrest of the dayBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskThe allocated method was not used in 13 patients due to \"human error or situations beyond the control of the paramedic\" (9 in the humeral IO group and 4 in the IV group). Success of insertion data was analysed on both an intention-to-treat and as-treated basis. Other outcomes were analysed as intention-to-treatIncomplete outcome data (attrition bias) Clinical outcomesLow riskAnalysed as intention-to-treatIncomplete outcome data (attrition bias) Subjective outcomesLow riskAnalysed as intention-to-treatSelective reporting (reporting bias)High riskProspectively registered (NCT01119807). Additional secondary outcomes were reported in the final report that were not mentioned in the registration record Selam 1983MethodsRandomised cross-over trialParticipantsSetting: hospital, France 6 patients with insulin-dependent diabetes M/F = 2/7; mean age (SE) = 35 (4) yearsInterventions• Intravenous group: implanted either surgically in the cephalic vein or directly in the subclavian vein by using a needle puncture technique • Subcutaneous group: catheter implanted in the subcutaneous tissue of the lateral abdomen • Intraperitoneal group: inserted surgically into the lateral abdomen under local anaesthesia through a 5 cm subumbilical laparotomy All groups were infused insulin Unclear who performed the insertionsOutcomesLocal site reactions*\^* Pain*\^* (how this was assessed is not described in the report) *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskNot describedBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskNot applicable (trial does not involve fluid administration)Blinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the effect estimate may have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Subjective outcomesLow riskNo exclusionsSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Slesak 2003MethodsParallel randomised trialParticipantsSetting: hospital geriatric department, Germany 96 hospitalised patients aged 60 years and over with mild to moderate dehydration • Intravenous group: (n = 48); M/F = 12/36; mean age (SD) = 85.3 (5.8) years • Subcutaneous group: (n = 14); M/F = 17/31; mean age (SD) = 85.3 (7.6) yearsInterventions• Intravenous group: 18 to 22 G peripheral catheters • Subcutaneous group: 21 G butterfly into thigh, abdomen or thorax Both groups infused with half-normal saline-glucose solutions for as long as clinically necessary Insertions performed by nurses and doctorsOutcomesTime to infusion¤*\^* Time with functional access¤*\^* Local site reactions (oedema, erythema, cellulitis, phlebitis, pain)*\^* Doctors and nurses feasibility of route scores‡*\^* (\'feasibility\' described in the trial report as \"with regard to the practical implementation and the occurrence of complications\") Patient discomfort‡*\^* (measured using a Likert-like scale, points ranging from 1 = very good to 6 = very bad) Volume of fluid infused¤*\^* Serum sodium*\^* Creatinine‡*\^* ‡*mean and SD estimated from reported median and IQR for analysis - moderate sample size therefore SD calculated as* = *range/4* ¤*mean and SD estimated from reported median and minimum-maximum values for analysis - moderate sample size therefore SD calculated as* = *range/4* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot describedAllocation concealment (selection bias)Unclear riskShuffled blocks of 6 sealed envelopes, each containing 3 of each treatmentBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesLow riskWe judge that measurement of these outcomes is not likely to be influenced by lack of blindingBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow riskNo exclusions reported. However, 13 patients in the SC group were switched to IV and 17 patients in the IV group were switched to SC. Data were analysed according to intention-to-treatIncomplete outcome data (attrition bias) Clinical outcomesLow riskNo exclusions reported. However, 13 patients in the SC group were switched to IV and 17 patients in the IV group were switched to SC. Data were analysed according to intention-to-treatIncomplete outcome data (attrition bias) Subjective outcomesLow riskNo exclusions reported. However, 13 patients in the SC group were switched to IV and 17 patients in the IV group were switched to SC. Data were analysed according to intention-to-treatSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement Spandorfer 2005MethodsParallel randomised trialParticipantsSetting: 24 hospitals, USA 148 children with mild to moderate dehydration aged 1 month to \< 10 years • Intravenous group: (n = 75); M/F = 39/36; mean age (range) = 2.4 (2.07) years • Subcutaneous group: (n = 73); M/F = 34/39; mean age (range) = 2.1 (1.72) yearsInterventions• Intravenous group: details of route not described • Subcutaneous group: details of route not described. Hyaluronidase used in all patients 20 ml/kg isotonic fluids over 1 hour Insertions performed by \"health care providers\"OutcomesFailure of route placement*\^* (definition of failure not specified in the report) Time to infusion*\^* Local site reactions (erythema, oedema, swelling)*\^* Clinicians\' perception of ease of route to perform*\^* Patient discomfort*\^* (assessed using the FLACC scale for those \< 3 years or FACES Pain Rating scale for those ≥ 3 years) Volume of fluid infused*\^* *\^data analysed as intention-to-treat*Notes-***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated randomisationAllocation concealment (selection bias)Low riskCentral randomisationBlinding of participants and personnel (performance bias) All outcomesHigh riskBlinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Outcomes related to parenteral route insertionHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedBlinding of outcome assessment (detection bias) Clinical outcomesUnclear riskData on these outcomes were not reportedBlinding of outcome assessment (detection bias) Subjective outcomesHigh riskLikely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biasedIncomplete outcome data (attrition bias) Outcomes related to parenteral route insertionLow risk1 patient in the IV group was excluded from the trial at the request of the parent. 15 patients in the IV group were switched to SC. Both intention-to-treat and as-treated data are presentedIncomplete outcome data (attrition bias) Clinical outcomesUnclear riskData on these outcomes were not reportedIncomplete outcome data (attrition bias) Subjective outcomesLow risk1 patient in the IV group was excluded from the trial at the request of the parent. 15 patients in the IV group were switched to SC. Both intention-to-treat and as-treated data are presentedSelective reporting (reporting bias)Unclear riskInsufficient information to permit judgement[^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25][^26][^27][^28]

Characteristics of excluded studies *\[ordered by study ID\]*
-------------------------------------------------------------

StudyReason for exclusionChavez-Negrete 1991Trial in which patients were randomised to receive an infusion of 7.5% NaCl + 6% dextran 60 or Ringer\'s lactate. Within each arm some of the patients received the assigned fluids intravenously and others intraosseously. However, the parenteral method for infusion was not determined at random, so the trial was not eligible for inclusion in this reviewIsmael 2012The parenteral methods under study were not used for infusion of fluids or medicationKlemenz 1997Not a RCT; the article is a letter describing the subcutaneous and intravenous methods for delivering fluidsKoshy 2005Not relevant to the review question; the purpose of the trial was to assess the effects of the infusion of analgesia on cancer painLee 2009The parenteral methods under study were not used for infusion of fluids or medicationMace 2013Not a RCT. The study evaluated the cost-effectiveness of subcutaneous fluid adminsitration compared to intravenous fluid administration in children with mild to moderate dehydrationMahalanabis 1970Not a RCT. The study explores the effect of intraperitoneal routes in dehydrated patients. All patients received fluids via both the intravenous and intraperitoneal routesMoulin 1991Not relevant to the review question; the purpose of the trial was to assess the effects of the infusion of analgesia on cancer painNelson 1997Cross-over study comparing intravenous and subcutaneous morphine. However, the order in which the patients received the methods was not randomised - all received intravenous morphine followed by subcutaneous morphinePaxton 2009Not a RCT. This is a prospective cohort study exploring intraosseous and intravenous accessRajani 2011Comparison of umbilical venous access versus intraosseous access under simulated conditions. Umbilical venous access was not an eligible type of interventionRansome-Kuti 1969Not a RCT. This is a case series report describing the outcomes of 91 dehydrated babies who were administered fluids via the intraperitoneal routeRobinson 1993The parenteral methods under study were not used for infusion of fluids or medicationSoremekun 2009Cross-over study comparing intravenous and subcutaneous glucose. However, the order in which the patients received the methods was not randomised - all received intravenous access first followed by subcutaneous accessTighe 1993Not a RCT. This is a case series report describing the outcomes of 9 dehydrated children who were administered fluids via the intravenous, intraosseous or intraperitoneal route. The route received was not allocated at random[^29][^30]

DATA AND ANALYSES
=================

Comparison 1.Intravenous versus intraosseous accessOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Insertion failures2242Risk Ratio (M-H, Fixed, 95% CI)3.89 \[2.39, 6.33\]2 Insertion failures (subgroup analysis child vs adult)2242Risk Ratio (M-H, Fixed, 95% CI)3.89 \[2.39, 6.33\] 2.1 Adult1182Risk Ratio (M-H, Fixed, 95% CI)3.24 \[2.00, 5.27\] 2.2 Child160Risk Ratio (M-H, Fixed, 95% CI)21.0 \[1.29, 342.93\]3 Time to infusion/placement4Mean Difference (Fixed, 95% CI)Totals not selected4 Average number of insertion attempts1Mean Difference (IV, Fixed, 95% CI)Totals not selected5 Dislodgement of device during infusion1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected6 Local site reactions1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected 6.1 Infection1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\]7 Clinician\'s perception of ease/feasibility of administration1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected8 Volume of fluids transfused1Mean Difference (IV, Fixed, 95% CI)Totals not selected9 Electrolyte level1Mean Difference (IV, Fixed, 95% CI)Totals not selected 9.1 Sodium1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 9.2 Potassium1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]10 Renal function1Mean Difference (IV, Fixed, 95% CI)Totals not selected 10.1 Urea1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 10.2 Creatinine1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]

Comparison 2.Intravenous versus subcutaneous accessOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Insertion failures3238Risk Ratio (M-H, Fixed, 95% CI)14.79 \[2.87, 76.08\]2 Insertion failures (sensitivity analysis - trial(s) with adequate allocation concealment)1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected3 Insertion failures (subgroup analysis child vs adult)3238Risk Ratio (M-H, Fixed, 95% CI)14.79 \[2.87, 76.08\] 3.1 Adult290Risk Ratio (M-H, Fixed, 95% CI)6.0 \[0.76, 47.39\] 3.2 Child1148Risk Ratio (M-H, Fixed, 95% CI)32.13 \[1.96, 525.87\]4 Time to infusion/placement1Mean Difference (IV, Fixed, 95% CI)Totals not selected5 Dislodgement of device during infusion1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected6 Time with functional access (days)1Mean Difference (IV, Fixed, 95% CI)Totals not selected7 Local site reactions9Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 7.1 Any5247Risk Ratio (M-H, Fixed, 95% CI)0.91 \[0.80, 1.02\] 7.2 Erythema4296Risk Ratio (M-H, Fixed, 95% CI)0.43 \[0.31, 0.61\] 7.3 Swelling1148Risk Ratio (M-H, Fixed, 95% CI)0.26 \[0.17, 0.41\] 7.4 Infection4211Risk Ratio (M-H, Fixed, 95% CI)3.70 \[1.06, 12.88\] 7.5 Phlebitis3181Risk Ratio (M-H, Fixed, 95% CI)5.04 \[1.14, 22.30\] 7.6 Oedema7453Risk Ratio (M-H, Fixed, 95% CI)0.42 \[0.25, 0.72\]8 Local site reactions (sensitivity analysis - trial(s) with adequate allocation concealment)3Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 8.1 Any3202Risk Ratio (M-H, Fixed, 95% CI)0.87 \[0.79, 0.96\] 8.2 Erythema3200Risk Ratio (M-H, Fixed, 95% CI)0.33 \[0.22, 0.49\] 8.3 Swelling1148Risk Ratio (M-H, Fixed, 95% CI)0.26 \[0.17, 0.41\] 8.4 Infection118Risk Ratio (M-H, Fixed, 95% CI)3.0 \[0.14, 65.16\] 8.5 Phlebitis118Risk Ratio (M-H, Fixed, 95% CI)3.0 \[0.14, 65.16\] 8.6 Oedema3202Risk Ratio (M-H, Fixed, 95% CI)0.25 \[0.06, 1.15\]9 Clinicians\' scores of feasibility of insertion1Mean Difference (IV, Fixed, 95% CI)Totals not selected 9.1 Doctors\' scores1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 9.2 Nurses\' scores1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]10 Clinician\'s perception of difficulty of insertion1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected11 Patients\' discomfort5Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 11.1 Pain3262Risk Ratio (M-H, Fixed, 95% CI)1.01 \[0.83, 1.22\] 11.2 Agitation2125Risk Ratio (M-H, Fixed, 95% CI)1.84 \[1.26, 2.70\]12 Patients\' discomfort (sensitivity analysis - trial(s) with adequate allocation concealment)2Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 12.1 Pain2166Risk Ratio (M-H, Fixed, 95% CI)0.97 \[0.81, 1.16\]13 Patient discomfort score1Mean Difference (IV, Fixed, 95% CI)Totals not selected14 Mortality2106Risk Ratio (M-H, Fixed, 95% CI)1.04 \[0.18, 5.92\]15 Mortality (sensitivity analysis - trial(s) with adequate allocation concealment)1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected16 Volume of fluids transfused4Mean Difference (IV, Fixed, 95% CI)Totals not selected17 Volume of fluids transfused (sensitivity analysis - trial(s) with adequate allocation)1Mean Difference (IV, Fixed, 95% CI)Totals not selected18 Electrolyte level1Mean Difference (IV, Fixed, 95% CI)Totals not selected 18.1 Sodium1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]19 Markers of renal function2Mean Difference (IV, Fixed, 95% CI)Subtotals only 19.1 Urea167Mean Difference (IV, Fixed, 95% CI)-11.29 \[-24.69, 2.11\] 19.2 Creatinine2138Mean Difference (IV, Fixed, 95% CI)-0.08 \[-0.33, 0.16\]

Comparison 3.Saphenous vein cutdown versus intraosseous accessOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Insertion failures1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected2 Time to infusion/placement (seconds)1Mean Difference (Fixed, 95% CI)Totals not selected

![Comparison 1 Intravenous versus intraosseous access, Outcome 1 Insertion failures.](CD011386-0001-f3){#d36e9787}

![Comparison 1 Intravenous versus intraosseous access, Outcome 2 Insertion failures (subgroup analysis child vs adult).](CD011386-0001-f4){#d36e9794}

![Comparison 1 Intravenous versus intraosseous access, Outcome 3 Time to infusion/placement.](CD011386-0001-f5){#d36e9801}

![Comparison 1 Intravenous versus intraosseous access, Outcome 4 Average number of insertion attempts.](CD011386-0001-f6){#d36e9808}

![Comparison 1 Intravenous versus intraosseous access, Outcome 5 Dislodgement of device during infusion.](CD011386-0001-f7){#d36e9815}

![Comparison 1 Intravenous versus intraosseous access, Outcome 6 Local site reactions.](CD011386-0001-f8){#d36e9822}

![Comparison 1 Intravenous versus intraosseous access, Outcome 7 Clinician\'s perception of ease/feasibility of administration.](CD011386-0001-f9){#d36e9829}

![Comparison 1 Intravenous versus intraosseous access, Outcome 8 Volume of fluids transfused.](CD011386-0001-f10){#d36e9837}

![Comparison 1 Intravenous versus intraosseous access, Outcome 9 Electrolyte level.](CD011386-0001-f11){#d36e9844}
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